

(19) DANMARK

(10) DK/EP 2924052 T3



Patent- og  
Varemærkestyrelsen

(12) Oversættelse af  
europæisk patentskrift

- (51) Int.Cl.: *C 07 K 19/00 (2006.01)* *A 61 K 39/395 (2006.01)* *C 07 K 14/705 (2006.01)*  
*C 07 K 16/28 (2006.01)* *C 07 K 16/46 (2006.01)* *C 12 N 15/62 (2006.01)*
- (45) Oversættelsen bekendtgjort den: **2019-09-30**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-07-17**
- (86) Europæisk ansøgning nr.: **13857338.1**
- (86) Europæisk indleveringsdag: **2013-11-20**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-09-30**
- (86) International ansøgning nr.: **KR2013010589**
- (87) Internationalt publikationsnr.: **WO2014081202**
- (30) Prioritet: **2012-11-21 KR 20120132431**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Pharmabcine Inc., 412, Daejeon Bio Venture Town , 1662, Yuseong-daero , Yuseong-gu, Daejeon 305-811, Sydkorea**
- (72) Opfinder: **KIM, Joong Kyu, 8-302 Sciencevill, Woncheon-dong, Yuseong-gu, Daejeon 305-370, Sydkorea**  
**YOO, Jin San, 2-101 Sciencevill, 257-22 Woncheon-dong, Yuseong-gu, Daejeon 305-370, Sydkorea**  
**LEE, Weon Sup, 106-606 Daelimdoore Apt., Sinsung-dong, Yuseong-gu, Daejeon 305-720, Sydkorea**  
**KIM, Sung Woo, 106-503 Daelimdoore Apt., Sinsung-dong, Yuseong-gu, Daejeon 305-720, Sydkorea**  
**SHIM, Sang Ryeol, 409-1501 Daeduk Tecnobelly 4-danji Apt., 666 Gwanpyung-dong, Yuseong-gu, Daejeon 305-509, Sydkorea**  
**YOO, Jin Sang, 201, 122-1 Sinsung-dong, Yuseong-gu, Daejeon 305-804, Sydkorea**  
**LEE, Young Ae, 3-304 Sambo villa, 22-38 Gajang-dong, Seo-gu, Daejeon 302-803, Sydkorea**  
**BYUN, Sang Soon, 24-1107 Samsung Apt., Oryu-dong, Jung-gu, Daejeon 301-788, Sydkorea**  
**LEE, Hyuk Joon, 207-804 Songkang Chungsol Apt., Songgang-dong, Yuseong-gu, Daejeon 305-752, Sydkorea**  
**KIM, Do Yun, 202 Donghyang villa, 54-7 Bokdae-dong, Heungdeok-gu, Chungcheongbuk-do 361-811, Sydkorea**  
**KIM, Yeun Ju, 202 Taesung villa, 124-13 Sinsung-dong, Yuseong-gu, Daejeon 305-804, Sydkorea**  
**CHOI, Jin Hee, 103, 142-19 Sinsung-dong, Yuseong-gu, Daejeon 305-804, Sydkorea**  
**NAHM, Kyung Hee, 508-502 Bansuk Maeul 5-danji Apt., Bansuk-dong, Yuseong-gu, Daejeon 305-749, Sydkorea**  
**NAM, Ju Ryung, 302, 368-7 Jeonmin-dong, Yuseong-gu, Daejeon 305-810, Sydkorea**  
**JEONG, Jong Geun, 102 cabinhouse, 370-7, Jeonmin-dong, Yuseong-gu, Daejeon 305-810, Sydkorea**  
**JEONG, Bo Young, 101-303 Songgang Hansol Apt., Songgang-dong, Yuseong-gu, Daejeon 305-758, Sydkorea**  
**LEE, Eun Jin, 705-1103 Bansuk Maeul 7-danji Apt., Bansuk-dong, Yuseong-gu, Daejeon 305-750, Sydkorea**  
**LEE, Seon Young, 303-605 Woosung 3-cha Apt., Jayang 3-dong, Gwangjin-gu, Seoul 143-773, Sydkorea**  
**PARK, In Sook, B01 Howon villa, Tanbang-dong, Seo-gu, Daejeon 302-223, Sydkorea**  
**LEE, Jin Sook, 103-1406 Doore Apt., Sinsung-dong, Yuseong-gu, Daejeon 305-720, Sydkorea**  
**YOON, Jae Bong, 202, 365-17 Jeonmin-gu, Yuseong-gu, Daejeon 305-810, Sydkorea**  
**KIM, Nam Ye, 103-2203 Wonang Maeul 1-danji Apt., Gwangeo 1-dong, Seo-gu, Daejeon 302-758, Sydkorea**  
**OH, Seon Hwan, 315-1001 Seonbi Maeul 3-danji Apt., Songchon-dong, Daedeok-gu, Daejeon 306-777, Sydkorea**

Fortsættes ...

LEE, Sang Hoon, 700 Flora Drive, Palo Alto, California 94306, USA

PARK, Mi Ju, 302 Donggwang Mension, 34-16 Okgye-dong, Jung-gu, Daejeon 301-090, Sydkorea

(74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**

(54) Benævnelse: **DUAL-TARGET-ANTISTOF MÅLRETTET MOD VEGFR-2 OG DLL4, OG FARMACEUTISK SAMMENSÆTNING OMFATTENDE SAMME**

(56) Fremdragne publikationer:

**WO-A1-2008/153237**

**US-A1- 2010 260 668**

**US-A1- 2012 258 108**

**SANG HOON LEE: "Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)", ARCHIVES OF PHARMACAL RESEARCH, PHARMACEUTICAL SOCIETY OF KOREA, HEIDELBERG, vol. 34, no. 8, 11 September 2011 (2011-09-11), pages 1223-1226, XP019950681, ISSN: 1976-3786, DOI: 10.1007/S12272-011-0821-9**

**FRANK KUHNERT ET AL: "Dll4-Notch signaling as a therapeutic target in tumor angiogenesis", VASCULAR CELL, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 18 September 2011 (2011-09-18), page 20, XP021111368, ISSN: 2045-824X, DOI: 10.1186/2045-824X-3-20**

**Y. FUNAHASHI ET AL: "A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis", CANCER RESEARCH, vol. 68, no. 12, 15 June 2008 (2008-06-15) , pages 4727-4735, XP055136020, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6499**

**HO, MITCHELL ET AL.: '2nd PEGS Annual Symposium on Antibodies for Cancer Therapy' MABS vol. 4, no. ISSUE., 30 April 2012, BOSTON, USA, pages 562 - 570, XP055255814**

**CAO, YIHAI: 'Tumor angiogenesis and molecular targets for therapy' FRONTIERS IN BIOSCIENCE vol. 14, no. 1, 2009, pages 3962 - 3973, XP008179297**

**CRAWFORD, YONGPING ET AL.: 'Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies' TRENDS IN PHARMACOLOGICAL SCIENCES vol. 30, no. 12, 2009, pages 624 - 630, XP 026776819**

**RIDGWAY, JOHN ET AL.: 'Inhibition of D114 signalling inhibits tumour growth by deregulating angiogenesis' NATURE vol. 444, no. 7122, 2006, pages 1083 - 1087, XP 002489428**

# DESCRIPTION

## [Technical Field]

**[0001]** The present invention relates to a novel form of a dual-target antibody in which an antagonist of DLL4 is bound to a terminal of an antibody targeting VEGFR-2 to additionally target human DLL4, DNA encoding the antibody, a recombinant expression vector including the same, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition including the dual-target antibody, and a method of measuring a DLL4 antagonist efficacy of the dual-target antibody.

## [Background Art]

**[0002]** Angiogenesis is a mechanism in which new blood vessels are generated from existing blood vessels by growth, division, migration, and the like, of an endothelial cell, plays an important role in normal growth processes including wound healing or female menstrual cycle (Risau, *Nature*, 386:671, 1997), and moreover, abnormally excessive angiogenesis is known to play a crucial role in diseases such as tumor growth and metastasis, age-related macular degeneration (ARMD), diabetic retinopathy, psoriasis, rheumatoid arthritis and chronic inflammation (Carmeliet and Jain, *Nature*, 407:249, 2000).

**[0003]** Hypothesis that tumor growth and metastasis are angiogenesis dependent, and therefore, a therapy focusing on anti-angiogenesis could be a new therapeutic agent for solid tumors was raised by Dr. J. Folkman in 1971. After that, research into a technology relating to inhibition of excessive angiogenesis mechanisms has attracted attention of many researchers (Ferrara and Kerbel, *Nature*, 438:967, 2005). A progressing aspect of the angiogenesis is determined by comprehensive balance of angiogenesis inducers and angiogenesis inhibitors, and is progressed by complex and multi-step sequential processes. In detail, various angiogenesis inducers including vascular endothelial growth factor (VEGF) secreted by tumor or injured tissues are bound to corresponding receptors of existing peripheral vascular endothelial cells to activate vascular endothelial cells, which increase permeability of vascular endothelial cells, and to secrete protease such as matrix metalloproteinase (MMP), which decomposes basement membrane and extracellular matrix surrounding vascular endothelial cells, such that the vascular endothelial cells escape from existing capillaries and migrate/proliferate toward the tissue secreting angiogenesis inducer. The migrated and proliferated vascular endothelial cells form an intravascular tube structure, and finally, pericyte which is a structural support of the vascular endothelial cell is introduced to achieve stable and mature blood vessel formation.

**[0004]** As described above, it was found that signaling of VEGF and a VEGF receptor

(VEGFR) bound to the VEGF is suppressed to ultimately inhibit angiogenesis, thereby obtaining therapeutic effects on various diseases age-related macular degeneration, diabetic retinopathy, psoriasis, rheumatoid arthritis and chronic inflammation, including growth and metastasis of tumor, and thus, development of various drugs capable of inhibiting VEGF activity has been ongoing.

**[0005]** Specifically, VEGF forms protein separation and purification and cDNA cloning by Dr. N. Ferrara group from Genentech in 1989 (Leung et al., *Science*, 246:1306, 1989). It is known so far that VEGF which is also referred to as VEGF-A has four isotypes (VEGF121, VEGF165, VEGF189, and VEGF206), and it is reported that among the four isotypes, VEGF165 is the most abundant in all human tissues except for placenta (Tisher et al., *J. Biol. Chem.*, 266:11947, 1991). It is known that VEGF is bound to receptors VEGFR-1 and VEGFR-2/KDR with significantly high affinity; however, signal of VEGF is mainly transferred through VEGFR-2 to induce mechanisms related to angiogenesis such as proliferation, migration, and the like, of vascular endothelial cells. Due to the above-described reasons, VEGF and VEGFR-2 become main targets for inhibiting angiogenesis mechanism induced by VEGF, and a number of these deal with VEGF and VEGFR-2 (Ellis and Hicklin, *Nature Rev. Cancer*, 8:579, 2008; Youssoufian et al., *Clin. Cancer Res.*, 13:5544s, 2007).

**[0006]** For example, Avastin (bevacizumab, Genentech) is a humanized antibody targeting VEGF-A (Ferrara et al., *Biochem. Biophys. Res. Comm.*, 333:328, 2005), which has received US FDA approval on treatment for metastatic colorectal cancer in 2004, non-small cell lung cancer in 2006, and Her-2 negative metastatic breast cancer in 2008, respectively, and is approved to treat Glioblastoma multiforme (GBM), and renal cancer. Currently, clinical trials on a variety of solid tumors are ongoing in order to expand indications. In addition, Lucentis which was developed in the same company, is an antibody prepared by cutting Fab fragments only from Avastin for good permeability of Lucentis when Lucentis is injected into retina in order to inhibit excessive angiogenesis around macula which is a main aspect of senile macular degeneration (Eter et al, *BioDrugs*, 20:167, 2006), and as a therapeutic agent for wet age-related macular degeneration (wet-ARMD), which has received US FDA approval in 2006.

**[0007]** As another antibody for treatment targeting VEGF, there is VEGF-trap manufactured by Regeneron (Holash et al., *PNAS*, 99:11393, 2002). VEGF-trap is a soluble decoy receptor in a form in which second immunoglobulin domain of VEGFR-1 and third immunoglobulin domain of VEGFR-2 are fused to human Fc, which has not received U.S. FDA approval yet, but has been ongoing in phase III stage for metastatic breast cancer, metastatic lung cancer, metastatic colorectal cancer, hormone refractory prostate cancer, and the like.

**[0008]** Meanwhile, examples of anti-angiogenesis antibodies targeting VEGFR-2 which is a receptor of VEGF include IMC-1121B (EP 1916001A2) manufactured by Imclone company, CDP-791 (PCT/GB02/04619) manufactured by UCB company, Tanibirumab (TTAC-0001) (WO2008/153237) developed by the present inventors and has been in a clinical trial, and the like.

**[0009]** IMC-1121B is a monoclonal antibody selected from a fully human Fab library, which has been ongoing in Phase III stage for metastatic breast cancer, and was entered in Phase III stage for stomach cancer in 2010. CDP-791 manufactured by UCB is a humanized antibody, which has been ongoing in phase II stage for non-small cell lung cancer in PEGylated Di-Fab form. Since this antibody does not have Fc, antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity may not be expected.

**[0010]** Lastly, Tanibirumab (TTAC-0001) developed by the present inventors is a monoclonal antibody selected from a fully human ScFv library, and is the only antibody having reactivity with flk-1 of mouse and rat origin (VEGFR-2 homologue) while simultaneously targeting VEGFR-2, which is one of important distinguishable features from IMC-1121B manufactured by Imclone (WO2008/153237). In particular, cross-species cross reactivity exhibited by Tanibirumab is possible to make a research into animal disease model to carry on future development of anti-cancer agent for specific cancer by stages, which makes related researches easier.

**[0011]** As described above, researches targeting VEGF and VEGFR-2 have been dramatically developed for last five years, and a number of therapeutic agents are developed by market and clinical studies.

**[0012]** Meanwhile, cells differentiated into Tip cell by VEGF / VEGFR-2 signaling strongly express DLL4 and are bound to Notch1 receptor present in surrounding cells, and cells in which Notch1 signaling pathway is activated are differentiated into stalk cells to form normal blood vessel tube structure, which proves that DLL4/Notch1 signaling pathway is one of the most important mechanisms for VEGF/VEGFR-2 path and angiogenesis (Dufraigne et al., *Oncogene*, 27:5132~5137, 2008).

**[0013]** It is known so far that DLL4 is one of ligands to a Notch receptor, and there are four kinds of Notch receptors (Notch 1 to 4) and five kinds of Notch ligands (Jagged-1, Jagged-2, DLL1, DLL3, and DLL4) in mammals. Notch signaling pathway is initiated by binding a Notch ligand of one cell to a Notch receptor of other cell, and is necessarily activated only by direct interaction between different cells (Bray SJ, *Nat Rev Mol Cell Biol.*, 7(9):678, 2006).

**[0014]** When the Notch ligand is bound to the Notch receptor, an ADAM metalloprotease is firstly activated to cleave a cellular membrane outer proximal site of the Notch receptor, and then a gamma-secretase complex is activated to cleave a cellular membrane inner proximal site of the Notch receptor, such that Notch Intracellular Domain (NICD) is isolated and migrates into the nucleus. NICD is bound to an RBPJ/CSL transcription factor to induce expression of Notch target genes such as basic helix-loop-helix proteins including Hes and Hey. The Notch signaling pathway determines proliferation/differentiation/apoptosis in accordance with the situation of corresponding cells, and plays an important role in maintenance of normal stem cells and cancer stem cells.

**[0015]** Basically, all Notch receptors are capable of being bound to all Notch ligands; however,

combinations of various bindings are selectively controlled in microenvironments of the corresponding cells. For example, DLL4 is strongly expressed on angiogenesis endothelial cells during a fetal development process, and is bound to Notch1 and Notch4 which are expressed in peripheral endothelial cells; however, DLL4-Notch1 binding is the most important in an exclusive way (Yan M, *Vasc Cell*, 2011), and angiogenesis progresses through the DLL4-Notch1 binding. The above-description is well found by gene deficiency test, and the like (Duarte et al., *Genes Dev*, 2004; Gale et al., *PNAS*, 2004; Krebs et al., *Genes Dev*, 2004).

**[0016]** Therefore, when the DLL4-Notch1 binding is suppressed, angiogenesis may be inhibited, and therefore, various diseases such as tumor, and the like, are capable of being treated. It has been already proven that when VEGF is inhibited by using Avastin (bevacizumab), and the like, in cancer treatment, angiogenesis is inhibited to decrease perfusion of the tumor, and a tumor size is decreased. Meanwhile, when binding with Notch1 expressed in peripheral cells while targeting DLL4 is inhibited, blood vessels are abnormally and largely generated (hypersprouting), but do not achieve complete function, which decreases perfusion of non-functional tumor, and as a result, the tumor size is reduced (Thurston et al., *Nat Rev Cancer*, 7(5):327, 2007).

**[0017]** Interestingly, when an antibody inhibiting VEGF and DLL4 is administered in xenograft animal experiments using several cancer cell lines performed in Genentech's research team, growth of the cancer is much strongly suppressed, as compared to a case in which an antibody inhibiting VEGF and an antibody inhibiting DLL4 are separately administered, respectively (Ridgway et al., *Nature*, 444(7122):1083, 2006). It suggests that signaling by DLL4/Notch1 path is not simply activated by VEGF/VEGFR-2 path, and various angiogenesis-related diseases such as tumor, and the like, are capable of being effectively treated by simultaneously inhibiting signalings by two paths.

**[0018]** In addition, it was found that DLL4 inhibition has an effect on both of a tumor being sensitive to VEGF/VEGFR-2 path inhibitor and a tumor being resistant to VEGF/VEGFR-2 path inhibitor (Ridgway et al., *Nature*, 444(7122):1083, 2006; Noguera-Troise et al., *Nature*, 444(7122):1032, 2006), which provides a significantly important clue to overcome resistance which currently and frequently occurs when drugs such as Avastin blocking VEGF are administered (including two cases of an intrinsic resistance in which Avastin is not effective from the beginning and acquired resistance in which an efficacy of Avastin is gradually falling over time).

**[0019]** Further, it was found from Oncomed's research team that DLL4 inhibition directly reduces frequency of cancer stem cells in tumor and inhibits tumor growth (Hoey et al., *Cell Stem Cell*, 2009), which suggests that DLL4 inhibition is possible to essentially block recurrence of cancer. Finally, resistance to anti-cancer chemotherapy and antibody therapeutic agents such as Herceptin, and the like, that are currently used for cancer treatment has a lot of relevance to the Notch signaling pathway and inhibition of DLL4/Notch1 path is also possible to overcome resistance of the anti-cancer chemotherapy and the antibody therapeutic agents such as Herceptin, and the like (Wang et al., *Biochim Biophys Acta*, 1806(2):258, 2010).

**[0020]** Document US 2010/0260668A1 discloses dual variable domain immunoglobulins and uses thereof. In particular, the document describes engineered multivalent and multispecific binding proteins, methods of making, and specifically uses in the prevention, diagnosis and/or treatment of diseases.

**[0021]** As described above, various angiogenesis-related diseases such as tumor, and the like, are capable of being effectively treated by simultaneously inhibiting signalings by two paths of VEGF/VEGFR-2 and DLL4/Notch 1. However, the development of drugs that are effective for this has not been made yet, and therefore, relevant development is urgently required.

### **[Summary of Invention]**

**[0022]** The present inventors conducted a research into development of a therapeutic agent capable of treating various angiogenesis-related diseases such as tumor, and the like, by more effectively and simultaneously suppressing signaling of two paths, VEGF/VEGFR-2 and DLL4/Notch1 to solve the above-described problems, and as a result, found that a dual-target antibody simultaneously targeting VEGFR-2 and DLL4 comprising a DLL4 antagonist, which is bound to a terminus of an antibody binding to VEGFR-2, wherein the antibody binding to VEGFR-2 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:1 to 3, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:4 to 6, wherein the DLL4 antagonist is the 11<sup>th</sup> and 12<sup>th</sup> calcium-binding EGF-like domain of human Notch1, and wherein the DLL4 antagonist is bound to N-terminal of light chain variable region of the antibody binding to VEGFR-2, effectively exhibits an effect of treating various angiogenesis-related diseases, and completed the present invention.

**[0023]** Another object of the present invention is to provide DNA encoding the dual-target antibody, and a recombinant expression vector including the same.

**[0024]** Another object of the present invention is to provide host cells transformed with the recombinant expression vector, and a method of producing the dual-target antibody according to the present invention, by using the host cells.

**[0025]** Another object of the present invention is to provide a pharmaceutical composition for treating angiogenesis related diseases comprising the dual-target antibody, wherein the angiogenesis related diseases is one or more selected from the group consisting of tumor growth, tumor metastasis, age-related macular degeneration (ARMD), diabetic retinopathy, psoriasis, rheumatoid arthritis and chronic inflammation.

### **[Description of Drawings]**

**[0026]**

FIG. 1 represents amino acid sequence of EGF-like domains 11 and 12 of Notch1 bound to DLL4.

FIG. 2 is a diagram of a vector PMC-201 v213 according to the present invention.

FIG. 3 represents results obtained by randomly expressing the vector according to the present invention by using a 293-T cell and confirming production of a purified dual-target antibody through SDS-PAGE.

FIG. 4 represents ELISA-analysis results of binding affinity to VEGFR-2 and human DLL4, of the dual-target antibody according to the present invention.

FIG. 5 represents Biacore-analysis results of binding affinity to human DLL4, of the dual-target antibody according to the present invention.

FIG. 6 represents Flow cytometer-analysis results of binding affinity to human DLL4, of the dual-target antibody according to the present invention.

FIG. 7 represents proliferation assay results on HUVEC, of the dual-target antibody according to the present invention.

FIG. 8 represents FACS-analysis results of phenomenon that the dual-target antibody according to the present invention competitively suppresses binding of Notch-Fc to human DLL4.

FIG. 9 represents luciferase luminescence assay results of phenomenon that the dual-target antibody according to the present invention suppresses promoter activation by Notch-1.

FIG. 10 represents western blotting-analysis results of phenomenon that an increase in notch intracellular domain (NICD) by activation of Notch-1 is suppressed, at the time of culturing the dual-target antibody according to the present invention and HUVEC in a culture dish coated with hDLL4.

FIG. 11 represents western blotting-analysis results of phenomenon that an increase in notch intracellular domain (NICD) by activation of Notch-1 is suppressed, at the time of co-culturing the dual-target antibody according to the present invention and HUVEC in a 293 cell line expressing hDLL4.

**[Best Mode]**

**[0027]** As far as it is not defined in other ways, all technical and scientific terms used in the present specification have the same meaning as being generally appreciated by those skilled

in the art to which the present invention pertains. In general, a nomenclature used in the present specification and experimental methods that are described below are well known in the present technical field and generally used.

**[0028]** In an embodiment for achieving objects of the present invention, the present invention provides a dual-target antibody simultaneously targeting VEGFR-2 and DLL4 comprising a DLL4 antagonist, which is bound to a terminus of an antibody binding to VEGFR-2, wherein the antibody binding to VEGFR-2 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:1 to 3, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:4 to 6, wherein the DLL4 antagonist is the 11<sup>th</sup> and 12<sup>th</sup> calcium-binding EGF-like domain of human Notch1, and wherein the DLL4 antagonist is bound to N-terminal of light chain variable region of the antibody binding to VEGFR-2.

**[0029]** It was confirmed that the dual-target antibody according to the present invention has an effect of inhibiting diseases caused by angiogenesis, by more effectively inhibiting angiogenesis, and has a binding affinity to each of targets VEGFR-2 and DLL4. In addition, it was confirmed from HUVEC proliferation inhibitory experiment that the dual-target antibody according to the present invention has excellent HUVEC proliferation inhibitory ability as compared to an antibody single-targeting VEGFR-2 only, for example, Tanibirumab.

**[0030]** In the invention, a term "dual-target antibody" means an antibody having a binding affinity or antagonism to one or more targets, and means an antibody in which two antibodies having a binding affinity or antagonism to different targets are bound to each other or an antibody having a binding affinity to one target is bound to a material having antagonism to the other target.

**[0031]** In addition, in the present invention, a term "antibody" includes both of polyclonal antibody and monoclonal antibody, wherein a fragment of an antibody molecule as well as a complete form including two light chains having the entire length and two heavy chains having the entire length may be used. The fragment of the antibody molecule means a fragment necessarily possessing an antigen binding function and includes a single-chain, Fv(scFv), Fab, F(ab'), F(ab')<sub>2</sub>, a single domain, and the like.

**[0032]** Preferably, the dual-target antibody according to the disclosure has a form in which an antibody which is specific for an angiogenesis factor or a receptor for such angiogenesis factor is bound to an angiogenesis antagonist, that is, an antagonist to an angiogenesis factor or a receptor for such angiogenesis factor.

**[0033]** In the dual-target antibody according to the disclosure, the antibody specifically bound to VEGFR-2 is usable without limitation as long as it is an antibody which is bound to the VEGFR-2 to inhibit VEGF/VEGFR-2 signaling, preferably, Tanibirumab or Bevacizumab, or variants thereof, but the present invention is not limited thereto.

**[0034]** In addition, the antagonist of DLL4 is usable without limitation as long as it is a substance having property of inhibiting DLL4/Notch1 signaling, particularly, a soluble receptor of which a cellular domain of Notch1 is deleted is preferred, but the present invention is not limited thereto. More preferably, as the antagonist of DLL4, 11st and 12nd EGF-like domains of a Notch1 receptor to DLL4 (hereinafter, referred to as "notch1 minimal decoy") may be particularly used.

**[0035]** The present description discloses that the antagonist of DLL4 is possible to be bound to a N-terminal or C-terminal, or the like, of a heavy chain or a light chain of the antibody specifically bound to VEGFR-2 without limitation, may be bound to an N-terminal of the heavy chain or light chain, or to an N-terminal of the light chain. According to an embodiment of the invention, the DLL4 antagonist is bound to the N-terminal of light chain variable region of the antibody binding to VEGFR-2.

**[0036]** The most preferred dual-target antibody referred to as PMC-201 provided in the present invention has a form in which the antagonist of DLL4, in particular, the Notch1 minimal decoy to DLL4 is linked to the terminal, in particular, the N-terminal of the light chain, of the antibody specifically bound to VEGFR-2. It is further described that the VEGFR-2-specific antibody is Tanibirumab and variants thereof.

**[0037]** The "angiogenesis" of the present invention means a cell phenomenon in which vascular endothelial cells are proliferated and reconstituted to form a new blood vessel from the existing blood vessel network. Angiogenesis factors promoting blood vessel generation, endothelial cell growth, blood vessel stability, and blood vessel formation are involved in the angiogenesis. The angiogenesis factors include members of vascular endothelial growth factor (VEGF) and VEGF family, placental growth factor (PIGF) family, platelet-derived growth factor (PDGF) family, DLL4, fibroblast growth factor family (FGF), TIE ligand (angiopoietin), ephrin, Del-1, fibroblast growth factor (acidic (aFGF) and basic (bFGF)), follistatin, granulocyte colony-stimulating factor (G-CSF), hepatocyte growth factor (HGF)/scatter factor (SF), interleukin-8 (IL-8), leptin, midkine, placental growth factor, platelet-derived endothelial cell growth factor (PD-ECGF), platelet-derived growth factor, in particular, PDGF-BB or PDGFR-beta, pleiotrophin (PTN), progranulin, proliferin, transforming growth factor-alpha (TGF-alpha), transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor (VEGF)/vascular permeation factor (VPF), and the like, but is not particularly limited thereto.

**[0038]** A term: "angiogenesis antagonist" of the present disclosure means a low-molecular weight material, polynucleotide, polypeptide, isolated protein, recombinant protein, antibody, or a conjugate thereof for a dual-target antibody, which directly or indirectly inhibit blood vessel generation, blood vessel formation, or undesirable blood vessel permeability. In addition, the angiogenesis inhibitor includes a material which is bound to the angiogenesis factor or a receptor thereof to block the angiogenesis from being activated. For example, the angiogenesis inhibitor includes antibodies or other antagonists to angiogenesis agents such as VEGF-A or a soluble receptor of VEGF-A (for example, a soluble KDR receptor or a Flt-1

soluble receptor), VEGF-trap, angiopoietin 2, Notch1 soluble receptor decoy, or fragments maintaining a binding affinity to the ligands of the materials thereof, but the present invention is not limited thereto.

**[0039]** As described above, preferably, the present invention provides the dual-target antibody in the form of a dual-target antibody targeting VEGFR-2 and DLL4 comprising a DLL4 antagonist, which is bound to a terminus of an antibody binding to VEGFR-2, wherein the antibody binding to VEGFR-2 comprises a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:1 to 3, and a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs:4 to 6, wherein the DLL4 antagonist is the 11<sup>th</sup> and 12<sup>th</sup> calcium-binding EGF-like domain of human Notch1, and wherein the DLL4 antagonist is bound to N-terminal of light chain variable region of the antibody binding to VEGFR-2.

**[0040]** Particularly, the VEGFR-2-specific antibody preferably consists of a heavy chain variable region of SEQ ID NO: 1 and a light chain variable region of SEQ ID NO: 4, a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 5, or a heavy chain variable region of SEQ ID NO: 3 and a light chain variable region of SEQ ID NO: 6. The present description also discloses an VEGFR-2-specific antibody which additionally includes the constant region in the variable region. Further disclosed are fragments or amino acid modifications of the VEGFR-2-specific antibody as long as the binding affinity to VEGFR-2 is possessed.

[Table 1]

<b>Sequences of Hv and Lv of the antibody binding to VEGFR-2 according to the present invention</b>				
<b>SEQ ID NO.</b>	<b>Antibody</b>	<b>Sequences</b>		
1	Heavy chain Variable region	AQPAMAQMQL	VQSGAEVKKP	GASVKLSCKA
		SGYTFSSYWM	HWVRQAPGQR	LEWMGEINPG
		NGHTNYNEKF	KSRVTITVDK	SASTAYMELS
		SLRSED TAVY YCAKIWGPSL	TSPFDYWGQG	TL
2	Heavy chain Variable region	QMQLVQSGAE	VKKPGASVKL	SCKASGYTFS
		SYWMHWVRQA	PGQRLEWMGE	INP GNGHTNY
		NEKFKSRVTI	TVDKSASTAY	MELSSLRSED
		TAVYYCAKIW	GPSL TSPFDY	WGQGTL
3	Heavy chain Variable region	QMQLVQSGAE	VKKPGASVKL	SCKASGYTFS

Sequences of Hv and Lv of the antibody binding to VEGFR-2 according to the present invention		
SEQ ID NO.	Antibody	Sequences
		SYWMHWVRQA      PGQRLEWMGE      INPGNGHTNY NEKFKSRVTI      TVDKSASTAY      MELSSLRSED TAVYYCAKIW      GPSLTSPFDY      WGQGTL
4	Light chain Variable region	SGVGSNFMLT      QPPSVSVSPG      KTARITCRGD
		NLGDVNVHWY      QQRPGQAPVL      VMYDADRPS GIPERFSGSN      SGNATLTIS      GVEAGDEADY YCQVWDRTSE      YVFGTGTKVT      VLG
5	Light chain Variable region	NFMLTQPPSV      SVSPGKTARI      TCRGDNLGDV NVHWYQQRPG      QAPVLVMYYD      ADRPSGIPER FSGSNSGNTA      TLTISGVEAG      DEADYYCQVW DRTSEYVFGT      GTKVTVLG
6	Light chain Variable region	NFMLTQPPSV      SVSPGKTARI      TCRGDNLGDV NVHWYQQRPG      QAPVLVMYYD      ADRPSGIPER FSGSNSGNTA      TLTISGVEAG      DEADYYCQVW DRTSEYVFGT      GTKVEIKRT

**[0041]** In addition, Notch1 minimal decoy to DLL4 according to the present invention preferably consists of an amino acid sequence of SEQ ID NO: 7. However, it is also obvious to those skilled in the art that as long as an antagonism to DLL4 is maintained, variants having variations, deletion, and insertion of amino acids are also included in the scope of the present invention.

**[0042]** In the dual-target antibody according to the invention, the antibody which is specifically bound to VEGFR-2 and the antagonist of DLL4 may be linked with each other by various methods such as binding via a linker, chemically direct binding, genetic fusion, and the like.

Preferably, the antibody and the antagonist may be linked by the binding via the linker, more preferably, by an amino acid linker. Preferable amino acid linker according to the present invention has an amino acid sequence of SEQ ID NO: 8.

[Table 2]

Amino acid sequences of Notch1 minimal decoy and amino acid linker according to the present invention		
SEQ ID NO.	Details	sequences
7	11st and 12nd EGF-like domains of Notch1 receptor	DVDECSLGAN PCEHAGKCIN TLGSFECQCL QGYTGPRCEI DVNECVSNPC QNDATCLDQI GEFQCICMPG YEGVHCE
8	amino acid linker	SGGGGSGGGGSGS

[0043] Therefore, a light chain-an amino acid linker-Notch1 minimal decoy protein of the dual-target antibody in which the Notch1 minimal decoy to DLL4 is linked to the light chain N-terminal of the dual-target antibody according to the present invention, via the amino acid linker has an amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.

[Table 3] **Amino acid sequences of a structure comprising light chain variable region of the dual-target antibody according to the present invention, in which Notch1 minimal decoy is bound thereto**

SEQ ID NO.	Sequences
9	DVDECSLGAN PCEHAGKCIN TLGSFECQCL QGYTGPRCEI DVNECVSNPC QNDATCLDQI GEFQCICMPG YEGVHCE <u>SGG</u> <u>GGSGGGGSGS</u> NFMLTQPPSV SVSPGKTARI TCRGDNLGDV NVHWYQQRPG QAPVLVMYYD ADRPSGIPER FSGSNSGNTA TLTISGVEAG DEADYYCQVW DRTSEYVFGT GTKVTVLG
10	DVDECSLGAN PCEHAGKCIN TLGSFECQCL QGYTGPRCEI DVNECVSNPC QNDATCLDQI GEFQCICMPG YEGVHCE <u>SGG</u> <u>GGSGGGGSGS</u> NFMLTQPPSV SVSPGKTARI TCRGDNLGDV NVHWYQQRPG QAPVLVMYYD ADRPSGIPER FSGSNSGNTA TLTISGVEAG DEADYYCQVW DRTSEYVFGT GTKVEIKRT

(sequences of amino acid linker is underlined)

**[0044]** In addition, the present invention provides polynucleotide sequences encoding the dual-target antibody and a recombinant vector including the same.

**[0045]** The polynucleotide sequence encoding the dual-target antibody may be easily derived from the amino acid sequences of SEQ ID NOS: 1 to 10 by those skilled in the art. In addition, polynucleotide encoding leader sequence is allowed to be positioned at the N-terminal of the dual-target antibody, which is usable in production of the dual-target antibody according to the present invention.

**[0046]** A term: "recombinant vector" in the present invention is an expression vector capable of expressing a target protein in an appropriate host cell, and indicates a gene construct including essential controlling elements operably linked to each other so as to express gene inserts.

**[0047]** A term: "operably linked" in the present invention means that nucleic acid expression regulation sequences and nucleic acid sequences encoding target protein are functionally linked with each other so as to perform general functions. An operable link with the recombinant vector may be conducted by using gene recombinant technologies well known in the art, and site-specific DNA cleavage and linkage may be easily conducted by using enzymes generally known in the art.

**[0048]** Appropriate expression vectors of the present invention may include signal sequence for membrane targeting or secretion in addition to expression control elements such as a promoter, an initiation codon, a termination codon, polyadenylation signal and an enhancer. The initiation codon and the termination codon are generally considered as portions of nucleotide sequences encoding an immunological target protein, and when a gene construct is administered, function should be exhibited in an injected subject and should be in frame with coding sequences. A general promoter may be constitutive or inducible. Prokaryotic cells have lac, tac, T3 and T7 promoters, but the present invention is not limited thereto. Eukaryotic cells have monkey virus 40 (SV40) promoter, mouse mammary tumor virus (MMTV) promoter, human immunodeficiency virus (HIV) promoter, for example, HIV long terminal repeats (LTR) promoter, moloney virus promoter, cytomegalovirus (CMV) promoter, Epstein Barr virus (EBV) promoter, Rous sarcoma virus (RSV) promoter, and also have  $\beta$ -actin promoter, human hemoglobin-, human muscle creatine-, human metallothionein- derived promoters, but the present invention is not limited thereto.

**[0049]** The expression vector may include a selective marker for selecting a host cell containing a vector. The selective marker is to screen a cell transformed with the vector, wherein markers providing a selectable marker phenotype such as drug resistance, auxotrophy, resistance to a cytotoxic agent, or expression of a surface protein may be used. Since only cells expressing the selectable marker survive in environment treated with the selective agent, a transformed cell is possible to be selected. In addition, in the case in which

the vector is a replicable expression vector, vector may include a replication origin which is a specific nucleic acid sequence initiating replication.

**[0050]** As a recombinant expression vector for inserting foreign genes, various vectors such as plasmid, virus, cosmid, and the like, may be used. The recombinant vector is not specifically limited in view of a kind as long as it expresses desired gene in various host cells of prokaryotic cells and eukaryotic cells, and produces desired protein; however, a vector capable of possessing strong expression with the promoter exhibiting strong activity while mass-producing the foreign protein in a form similar to a natural state is preferred.

**[0051]** In order to express the dual-target antibody according to the present invention, various expression host/vector combinations may be used. Examples of an expression vector which is appropriate for the eukaryotic host include expression regulatory sequences derived from SV40, bovine papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus, and retro virus, but the present invention is not limited thereto. The expression vector usable in a bacterial host includes bacterial plasmids obtained from *Escherichia coli*, such as pET, pRSET, pBluescript, pGEX2T, pUC vector, col E1, pCR1, pBR322, pMB9, and derivatives thereof, plasmid having a large range of host, such as RP4, phage DNA including significantly various phage lambda derivatives such as gt10, gt11, NM989, and other DNA phages such as M13 and filamentous single strand DNA phage. An expression vector useful for a yeast cell is 2 plasmid and derivatives thereof. A vector useful for an insect cell is pVL941.

**[0052]** According to another embodiment of the present invention, the present invention provides a host cell transformed with the recombinant vector. The recombinant vector is inserted into the host cell to form a transformant. Appropriate host cells of the vector may include a prokaryotic cell such as *Escherichia coli*, *Bacillus subtilis*, *Streptomyces* sp., *Pseudomonas* sp., *Proteus mirabilis* or *Staphylococcus* sp. In addition, the host cell may be a eukaryotic cell including fungi such as *Aspergillus* sp., yeast such as *Pichia pastoris*, *Saccharomyces cerevisiae*, *Schizosaccharomyces* sp. and *Neurospora crassa*, and other lower eukaryotic cells and higher eukaryotic cells from an insect. In addition, host cells may be derived from plants and mammals. Preferably, a monkey kidney cell 7 (COS7), an NSO cell, SP2/0, a chinese hamster ovary (CHO) cell, W138, a baby hamster kidney (BHK) cell, MDCK, myeloma cell line, HuT 78 cell and HEK293 cell, and the like, are available, but the present invention is not limited thereto. In particular, a CHO cell is preferred.

**[0053]** A term "transformation into a host cell" in the present invention may include any method in which nucleic acids are introduced into an organism, a cell, a tissue, or an organ, and may be performed by selecting appropriate standard technology depending on the host cell as known in the art. The method for transformation includes electroporation, protoplast fusion, calcium phosphate (CaPO<sub>4</sub>) precipitation, calcium chloride (CaCl<sub>2</sub>) deposition, stirring with silicon carbide fibers, agrobacterium-mediated transformation, polyethyleneglycol (PEG), polyethyleneimine (PEI), dextran sulfate, lipofectamine and dryness/inhibition-mediated transformation; however, the present invention is not limited thereto.

**[0054]** According to another embodiment of the present invention, the present invention provides a method of producing the dual-target antibody according to the present invention, including culturing host cells transformed with the recombinant vector.

**[0055]** The dual-target antibody according to the invention is preferably obtained by expression and purification by a gene recombinant method. Specifically, gene sequence encoding a heavy chain variable region or a heavy chain entire region of the antibody and gene sequence encoding a light chain variable region or a light chain entire region may be expressed in a single vector or in two vectors, separately, wherein the amino acid linker and/or gene sequence encoding the antagonist of DLL4 may be linked to a site corresponding to the N-terminal of the heavy chain or the light chain to induce expression in a cell expression system, thereby producing the dual-target antibody according to the present invention, but the present invention is not limited thereto.

**[0056]** Specifically, the method of producing the dual-target antibody may include: producing a recombinant vector by inserting nucleotide sequences encoding the dual-target antibody of the present invention into a vector; transforming the recombinant vector into a host cell and culturing the transformant; and isolating and purifying the dual-target antibody from the incubated transformant.

**[0057]** More specifically, the dual-target antibody may be mass-produced by culturing the transformant having expressed recombinant vector in a nutrient medium, wherein medium and incubation condition may be appropriately selected depending on a host cell. Conditions such as temperature, pH of medium, incubation time, and the like, may be appropriately controlled so as to be appropriate for growth and development of cells and mass-production of protein at the time of culturing.

**[0058]** Recombinantly-produced peptide or protein as described above may be recovered from medium or cell degradation. In the case of a membrane-coupled type, the peptide or the protein may be isolated from membrane by using an appropriate surfactant solution (for example: tritone-X 100) or enzymatic cleavage. Cells used in expression of the dual-target antibody may be destroyed by various physical or chemical means such as freeze-thaw purification, sonic treatment, mechanical damage and cell decomposing agent, and may be isolated and purified by general biochemical isolation technology (Sambrook et al., Molecular Cloning: A laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press(1989); Deutscher, M., Guide to Protein Purification Methods Enzymology, Vol. 182. Academic Press. Inc., San Diego, CA(1990)). Electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography (ion exchange chromatography, affinity chromatography, immunosorbent chromatography, size exclusion chromatography, and the like), isoelectric focusing, and various changes and complex methods are available, but the present invention is not limited thereto.

**[0059]** According to another embodiment of the present disclosure, the present invention provides a composition for inhibiting angiogenesis or treating cancer, the composition including

the dual-target antibody. A term "anti-cancer" in the present invention includes "prevention" and "treatment"; wherein "prevention" means all behaviors in which cancer is inhibited or delayed by injection of the composition containing the antibodies of the present invention, and "treatment" means all behaviors in which symptoms of cancer are improved or changed in an advantageous way by the injection of the composition containing the antibodies of the present invention.

**[0060]** Cancers or tumors capable of being treated by the composition of the present invention are not particularly limited, but include solid tumor and blood cancer. Preferably, examples of cancer include colon cancer, colorectal cancer, gastric cancer, breast cancer, lung cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, pancreas cancer, cervical cancer, brain cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, parathyroid cancer, kidney cancer, esophageal cancer, biliary tract cancer, testis cancer, rectal cancer, head and neck cancer, cervical cancer, ureter cancer, osteosarcoma, neurocytoma, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma, neuroglioma, and the like.

**[0061]** The anti-cancer composition of the present invention may additionally include a pharmaceutically acceptable carrier. For oral administration, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent, pigment, flavouring, and the like, may be used. For an injection, a buffering agent, a preservative, a soothing agent, a solubilizing agent, an isotonic agent, a stabilizer may be mixed to be used. For topical administration, a basic substance, an excipient, a lubricant, a preservative, and the like, may be used. The pharmaceutical composition in the present invention may be mixed with the above-described pharmaceutically acceptable carrier to have various formulations. For example, for oral administration, the formulation may be formed as tablets, troches, capsules, elixir, suspension, syrup, wafer, and the like. For injection, the formulation may be prepared in a single unit dosage ampoule or in a multiple dosage form. In addition, the anti-cancer composition may typically include a surfactant facilitating movement including passage through membranes. Examples of the surfactant include materials derived from steroids, cationic lipids such as N-[1-(2,3-dioleoyl)propyl]-N,N,N-trimethylammoniumchloride (DOTMA), various compounds such as cholesterol hemisuccinate, phosphatidyl glycerol, and the like.

**[0062]** According to another embodiment of the present invention, the present invention provides a pharmaceutical composition for use in a method of treating cancer and inhibiting cancer growth by administering the dual-target antibody or the composition containing the dual-target antibody of the present invention to a subject. The composition containing the dual-target antibody according to the present invention may be administered in a pharmaceutically effective amount in order to treat cancer cell or metastasis thereof or to inhibit cancer growth. The administration amount may vary according to various factors such as cancer type, age and body weight of a patient, characteristics and severity of symptoms, kinds of current treatment, the number of treatments, administration type and route, and the like, and may be easily determined by experts in the corresponding art. The composition of the present invention may be administered together with the above-described pharmacological or

physiological ingredients, or may be administered sequentially. In addition, the composition of the present invention may be administered in combination with additional conventional therapeutic agent, and may be administered sequentially or simultaneously with the conventional therapeutic agents. The administration may be a single or a multiple administration. It is important to administer an amount at which the maximum effect is obtained with a minimum amount without side effects in consideration of all of the above-described factors, and may be easily determined by those skilled in the art.

**[0063]** In the present invention, a term "subject" means a mammal suffering from a condition or disorder which is to be alleviated, inhibited or treated, or with such risk, by administering the dual-target antibody according to the present invention, preferably, a human.

**[0064]** In the present invention, a term "administration" means an introduction of a predetermined material to a subject by any appropriate method, wherein the composition containing the dual-target antibody of the present invention may be administered by any general route as long as the composition arrives at a desired tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, intrarectal administration may be used, but the present invention is not limited thereto. However, since protein is digested in the case of oral administration, an oral composition is preferred to be provided by coating an active agent thereon or to be formulated so as to protect the composition from being digested in the stomach. In addition, the pharmaceutical composition may be administered by any apparatus in which an active agent is movable to a target cell.

**[0065]** In addition, the present disclosure provides a method of measuring DLL4 antagonist efficacy of the dual-target antibody, the method including measuring Notch 1 activity by co-culture of a cell line expressing human DLL4 (hDLL4) or a recombinant cell line with human umbilical vein endothelial cells (HUVEC).

**[0066]** In the present disclosure, the Notch 1 activity is characterized by measuring an expression amount of NICD, and when the Notch ligand is bound to the Notch receptor, an ADAM metalloprotease is firstly activated to cleave a cellular membrane outer proximal site of the Notch receptor, and then a gamma-secretase complex is activated to cleave a cellular membrane inner proximal site of the Notch receptor, such that Notch Intracellular Domain (NICD) is isolated and migrates into the nucleus. NICD is bound to an RBPJ/CSL transcription factor to induce expression of Notch target genes such as basic helix-loop-helix proteins including Hes and Hey.

**[0067]** The measuring of the expression amount of NICD is performed by a method selected from the group consisting of SDS-PAGE, western blotting, immunohistochemical staining, immuno-staining, immunofluorescence, ELISA assay (direct measurements), and luciferase assay (indirect measurement), but may be performed by any known method for measuring protein expression in the art without limitation. In the present disclosure, the expression

amount of NICD was preferably measured by western blotting.

**[0068]** Specifically, co-culture of the cell line expressing human DLL4 (hDLL4) or the recombinant cell line with HUVEC may be performed by including steps of (a) culturing HUVEC; and (b) reacting 293 cell line over expressing hDLL4 (293-hDLL4) and the dual-target antibody and performing treatment in the HUVEC cultured in the step (a) to achieve co-culture. It was confirmed that the expression amount of NICD exhibited by Notch-1 activation was reduced by the dual-target antibody PMC-201 by the co-culture method in Examples of the present invention.

**[0069]** In addition, according to the method for measuring hDLL4 antagonist efficacy of the dual-target antibody which is characterized in that Notch 1 activity is measured by the expression amount of NICD, NICD promoter activity may be measured with the NICD amount by using a luciferase assay method, and hDLL4 antagonist efficacy of the dual-target antibody may be measured by treating and culturing the HUVEC and the dual-target antibody PMC-201 in hDLL4-coated plates and measuring the NICD amount in the HUVEC, as confirmed in other Examples of the present invention.

**[0070]** Hereinafter, the present invention will be described in more detail with reference to the following Examples. However, the following examples are provided only for exemplifying the present invention, and it will be obvious to those skilled in the art that it is not construed to limit the scope of the present invention by these examples.

#### **Example 1 Production of expression vector for temporary production of dual-target antibody PMC-201**

**[0071]** DNA encoding Notch1 minimal decoy (calcium-binding EGF-like domains 11 and 12 of a Notch1) bound to hDLL4 was obtained by gene synthesis (including gene optimization, GeneArt, Germany) after identifying amino acid base sequences (FIG. 1 and SEQ ID NO: 7) of corresponding domain.

**[0072]** 77 amino acid base sequences were cloned to the light chain N-terminal of Tanibirumab (see TTAC0001 disclosed in International Patent Application No. PCT/KR07/003077) expression vector, by using a G4S linker (S GGGG SGGGGS GS) consisting of 13 amino acids to produce a dual-target antibody PMC-201 expression vector with optimized expression in 293-T cell line (ATCC, CRL-11268 <sup>TM</sup>) (FIG. 2). The confirmed recombinant vector was named as 'PMC-201-v213'.

#### **Example 2: Production and Identification of dual-target antibody PMC-201**

**[0073]** Random expression of the completed expression vector PMC-201-v213 into a 293T cell

by transduction was induced, and occurrence of the expression was confirmed by SDS-PAGE and western blotting. The transduction was used by lipofectamine™ 2000 (Invitrogen #11668-019, U.S.A), and was followed by instruction of the manufacturer. Briefly,  $5 \times 10^5$  per well of 293T cells were inoculated into 6-well plates containing  $\alpha$ MEM medium (Welgene, Republic of Korea), and then allowed to stand in CO<sub>2</sub> (5%) humidified incubator at 37°C for 24 hours, thereby achieving dense culturing having a cell density of about 80% to 90%. 2  $\mu$ g of the recombinant vector (PMC-201-v213) and 6  $\mu$ l of lipofectamin™ 2000 were diluted in 250  $\mu$ l of serum-free  $\alpha$ MEM mediums, respectively, and left at room temperature for 5 minutes.

**[0074]** A DNA dilution solution was mixed with lipofectamin™ 2000 dilution solution and allowed to react at room temperature for 20 minutes, to form DNA-lipofectamin™ 2000 complex. After existing medium was removed from the incubated cell, 500  $\mu$ l of DNA-lipofectamin™ 2000 complex and 500  $\mu$ l of serum-free  $\alpha$ MEM medium were added to each well, and incubated in a CO<sub>2</sub> incubator at 37°C for 6 hours. 1 ml  $\alpha$ MEM medium containing 20% dialyzed fetal calf serum was added thereto and incubated for 48-72 hours. Then, only the supernatant was separated, and whether or not the antibody was expressed was confirmed by SDS-PAGE. SDS-PAGE was performed by methods known in the art, and samples were used as follows: 12% SDS-polyacrylamide Gel, PVDF membrane (Millipore #IPVH00010, U.S.A.), HRP-conjugated goat anti-human IgG(kappa) antibody, and HRP-conjugated goat anti-human IgG(Fc) antibody (Pierce, U.S.A.).

**[0075]** As a result, it was confirmed that the dual-target antibody PMC-201 was expressed by SDS-PAGE and western blotting, and purified antibodies having purity of 95% or more were obtained by Fast protein liquid chromatography (FPLC) using Protein A affinity column, SP-sepharose column, and size exclusion column (FIG. 3).

### **Example 3: Binding affinity test of Dual-Target Antibody PMC-201**

#### **3-1 : Binding affinity test to VEGFR-2 and hDLL4**

**[0076]** A binding affinity assay confirming whether or not the dual-target antibody PMC-201 was bound to VEGFR-2 and hDLL4 was performed by using ELISA. 1  $\mu$ g/ml of extracellular domains 1 to 3 of VEGFR-2 (hereinafter, referred to as VEGFR-2 ECD) and DLL4 were each divided and coated in a 96-well plate at room temperature for 2 hours, and a blocking reaction was performed at room temperature for 2 hours, using 2% skim milk/PBS.

**[0077]** After the plates after the blocking was finished was washed with PBS, previously prepared Tanibirumab and PMC-201 at various concentrations (0.18 to 3000 ng/ml) at room temperature were added to wells coated with VEGFR-2 ECD or hDLL4, and allowed to react at room temperature for 1 hour. After the reaction was finished, the product was washed with PBS, and then 1: 2000 dilution of HRP-conjugated goat anti-human IgG antibody (Pierce,

U.S.A.) was added as a secondary antibody and reacted at room temperature for 30 minutes. A colorimetric reaction was induced by TMB substrate reagent (BD Biosciences #555214, U.S.A.) and was stopped by adding 50  $\mu\text{l}$  of 2N sulfuric acid ( $\text{H}_2\text{SO}_4$ ) solution. Measurement of the colorimetric reaction was performed at absorbance of 450 nm and 650 nm by using a microplate reader (Tecan, Switzerland).

**[0078]** As a result, it was confirmed that Tanibirumab and PMC-201 had similar binding affinity in VEGFR-2; however, it was confirmed that only the PMC-201 had a binding affinity in hDLL4 (FIG. 4).

### **3-2 : Affinity Analysis of PMC-201 and human DLL4**

**[0079]** In order to calculate Kd (dissociation constant) of PMC-201 to human DLL4, BIACORE® 3000 (GE Healthcare) was used, and CM5 chip was used. The dissociation constant is similar to Km value, and is used as an affinity index of an enzyme to a substrate in an enzyme-substrate complex. The affinity between the enzyme and the substrate is increased as the dissociation constant is decreased.

**[0080]** The sample was immobilized by using 400mM EDC (N-ethyl-N'-(dimethylaminopropyl) Carbodiimide), 100mM NHS (N-Hydroxysuccinimide), and 1M ethanolamine hydrochloride (pH 8.5) that are an Amine Coupling Kit (GE Healthcare), and 20mM sodium hydroxide as a generation buffer, and 1XPBS as an immobilization buffer were diluted, and then the analysis sample was 1:40 diluted in 10mM acetate (pH 5.0) (GE Healthcare). The sample was immobilized at 4000RU (Response Unit). A buffer for measuring adsorption of the analysis sample was a HBS-EP buffer (GE Healthcare). DLL4s having measurement concentrations of 4.9, 9.7, 19.5, 39.1, 78.1, 156.3, 312.5nM as an antigen were serial-diluted so as to have a final volume of 200 $\mu\text{l}$  by using an HBS-EP buffer. Five concentrations of seven concentrations were selected and fitted. A concentration of the used generation buffer was selected by confirmation with about 10% higher than a base line by using sodium hydroxide, after the sample (156.3nM) was subjected to a binding step and a dissociation step for preliminary experiment before actual analysis. Affinity of the analysis sample was measured under conditions in which an analysis flow rate was 30 $\mu\text{l}/\text{min}$ , a binding section was 60 seconds, and a dissociation was 300 seconds.

**[0081]** As the analysis result of the affinity for each batch, each affinity was confirmed in PMC-201 and Notch-1 Fc, and the dual-target antibody PMC-201 of the present invention had higher affinity as compared to Notch-1 Fc (FIG. 5).

### **3-3 : Measurement of binding affinity of hDLL4 and PMC-201 expressed on cell surface**

**[0082]** ELISA and Biacore were used to measure binding affinity of PMC-201 to hDLL4

immobilized in a solid-phase, and FACS analysis was performed to confirm whether or not PMC-201 was bound to hDLL4 expressed on the cell surface (FIG. 6).

**[0083]** First, in order to produce 293 pool and a cell line expressing hDLL4 (SEQ ID NO: 12 amino acid sequence), coding sequence of hDLL4 (SEQ ID NO: 11 sequence) in which gene optimization was performed was cloned at restriction enzyme BamHI and EcoRI positions of pcDNA3.1 (+) by Geneoptimizer of GeneArt to construct pcDNA-hDLL4. Then, the pcDNA-hDLL4 vector was transduced into 293 cells. The transduction was used by using lipofectamine™ 2000 (Invitrogen #11668-019, U.S.A), and was followed by instruction of the manufacturer. Briefly,  $1 \times 10^6$  of 293 cells were inoculated into 100 mm well plates containing  $\alpha$ MEM medium (Welgene, Republic of Korea), and then incubated in CO<sub>2</sub>(5%) humidified incubator at 37°C for 24 hours so as to have cell density of about 20%. 16  $\mu$ g of vector (DLL4 pcDNA3.1) and 40  $\mu$ l of lipofectamin™ 2000 were diluted in 1 ml of serum-free  $\alpha$ MEM medium and incubated at room temperature for 5 minutes, and then DNA dilution solution was mixed with lipofectamin™ 2000 dilution solution, and reacted at room temperature for 20 minutes to form a DNA-lipofectamin™ 2000 complex. After the existing medium was removed from the incubated cells, 1 ml of DNA-lipofectamin™ 2000 complex and 9 ml of serum-free  $\alpha$ MEM medium were added to each well, and incubated in a CO<sub>2</sub> humidified incubator at 37°C for 6 hours, then, the medium was replaced with a DMEM medium containing 10% dialyzed fetal calf serum. Then, the medium was incubated at 37°C for 72 hours, cells were separated by Trypsin-EDTA, and then, DMEM medium containing 10% dialyzed fetal calf serum and neomycin (G418, 500  $\mu$ g/ml) were added and incubated. After 72 hours, the medium was replaced with a medium of which G418 concentration was increased by 1 mg/ml, and incubated under the same condition for about 1 week until colonies were formed. Each colony was treated with Trypsine-EDTA in plates having colonies formed therein, and was moved to a 24-well plate. DMEM medium containing 10% dialyzed fetal calf serum and neomycin (G418, 500  $\mu$ g/ml) were added and incubated, and all growing colonies were collected and incubated in a pool state.

**[0084]** After 1 week, FACS analysis was performed with anti-hDLL4 antibody (Biolegend, U.S.A.) in a pool state to confirm hDLL4 expression, and 23 kinds of single colonies were selected and subincubated in 6-well plate and 100 mm plate, respectively and incubated in DMEM medium containing 10% dialyzed fetal calf serum and neomycin (G418, 500  $\mu$ g/ml). One kind of cell favorably expressing hDLL4 was selected among single colonies, and named as 293-hDLL4, and used for DLL4 antagonist efficacy-related analysis of PMC-201.

**[0085]** FACS analysis was conducted in order to confirm that PMC-201 was favorably bound to 293-DLL4 pool. First, a sufficient number ( $1 \times 10^6$  or more per FACS sample) of 293-DLL4 pool was incubated, and made as single cell with Trypsin-EDTA, and 2 ml of 1x FACS buffer (0.2% BSA in PBS) was added and mixed well, followed by centrifugation at 1200 rpm for 3 minutes. A supernatant was discarded and cells at the bottom were primarily stained with 10 nM concentration of PMC-201, Notch-1 Fc, and Tanibirumab with ice for 20 minutes, washed with 1X FACS buffer, and were secondarily stained (20 minutes in ice) with PE-anti-human Fc

antibody and washed. Then, flow cytometry; FACSCalibur was used for measurement.

**[0086]** As a result obtained by measuring whether or not PMC-201 was bound to hDLL4 expressed on cell surface, it was confirmed that PMC-201 had similar binding affinity to Notch-1 Fc (FIG. 6).

**Example 4: Analysis of HUVEC proliferation ability after treatment of dual-target antibody PMC-201**

**[0087]** Cell proliferation ability analysis was performed to confirm change in proliferation ability of Human umbilical vein endothelial cell (HUVEC) (Lonza, Switzerland), after treatment of the dual-target antibody PMC-201 according to the present invention. HUVEC was incubated by using phenol red-free M199 medium (Invitrogen, U.S.A.) containing 20% fetal calf serum (Hyclone, U.S.A.), 100 units/**Mℓ** of penicillin (Hyclone, U.S.A.), 100 **μg/Mℓ** of streptomycin (Hyclone, U.S.A.), 3 **μg/Mℓ** of fibroblast growth factor (Upstate Biotechnology, U.S.A.) 5 units/**Mℓ** of heparin (Sigma-Aldrich, U.S.A.), in an incubator at 37°C with 5% CO<sub>2</sub> humidified mixed air. These cells were incubated in 24-well plates at density of 2 x 10<sup>4</sup> cell/well for 24 hours in order to analyze survival rate of HUVEC. Then, cells were washed with M199 medium twice, and incubated under a low serum concentration condition in M199 medium containing 1% fetal calf serum (Hyclone, U.S.A.) for 6 hours. Various concentrations of antibodies were pre-treated in cells for 30 minutes, and treated with 20 ng/**Mℓ** VEGF (R&D systems, U.S.A.). After incubation for 48 hours, cells were treated with WST-8 (Dojindo, Japan) for 2 hours, absorbance at 450 nm wavelength was measured, and cell proliferation ability under each condition was compared to each other.

**[0088]** As a result, it was confirmed from cell proliferation ability assay on initially incubated HUVEC that dual-target antibody PMC-201 could more strongly inhibit proliferation ability of HUVEC induced by VEGF as compared to the parent antibody Tanibirumab (FIG. 7).

**Example 5: Analysis of competitive Human DLL4 binding affinity using FACS**

**[0089]** FACS analysis was performed to confirm whether or not PMC-201 was competitively bound to hNotch1-Fc bound to 293-hDLL4 cell line. First, a sufficient number (1 x 10<sup>6</sup> or more of cells per FACS sample) of 293-hDLL4 were incubated and treated with Trypsin-EDTA to be isolated into single cells, and then, 2 **Mℓ** of 1 X FACS buffer (0.2% BSA in PBS) was added. Then, isolated single cells were recovered and centrifuged at 1,200 rpm for 3 minutes, and then supernatant was discarded. 16 **μg/Mℓ** of Tanibirumab or PMC-201 and 1 **μg/Mℓ** of rhNotch1-Fc having labeled Alexa-488 (Zenon, #Z-25402) were added to the cells at the bottom, primarily stained in ice for 30 minutes, washed with 1X FACS buffer, and measured by flow cytometry (FACSCalibur).

**[0090]** As a result, it was confirmed that the binding of rhNotch1-Fc bound to the HUVEC was four-times decreased in consideration of Geometric mean by PMC-201. Meanwhile, Tanibirumab could not inhibit the binding of rhNotch1-Fc antibody, which is similar to an untreated antibody group (FIG. 8).

#### **Example 6 Analysis of Promoter Activity by Notch-1**

**[0091]**  $1 \times 10^5$  LS174T cells (colon cancer cell line; ATCC, CL-188™) were incubated in RPMI medium containing 10% of fetal calf serum for 24 hours, and 0.8  $\mu\text{g}$  of Notch Signal reporter DNA contained in Signal Reporter Assay Kit (#336841 CCS-014L, QIAGEN) and 2  $\mu\text{l}$  of lipofectamine (#11668-500; Invitrogen) were mixed with 100  $\mu\text{l}$  of opti-MEM media and allowed to stand for 20 minutes, and then 400  $\mu\text{l}$  of opti-MEM was added for transfection to incubate cells for 6 hours. After 6 hours, the medium was replaced with an MEM medium containing 10% fetal calf serum, and incubated overnight. Next day, Tanibirumab and PMC-201 (each of 20 mg/ml) were mixed and pre-treated in  $1 \times 10^5$  of 293-hDLL4 cells for 1 hour, then co-cultured with LS174T cells transfected with Notch Signal reporter DNA for 24 hours. DAPT (5 mM) was not pre-treated and 293-hDLL4 cell was mixed with the transfected LS174T cells, and co-cultured for 24 hours.

**[0092]** DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) is generally known to inhibit Notch 1 activity, and inhibit activity of  $\gamma$ -secretase to decrease an increase in NICD production (Andrea Geling et al., EMBO Rep., :3(7):688, 2002; Ie-Ming Shih and Tian-Li Wang, Cancer Research, 67:1879, 2007).

**[0093]** After co-culture for 24 hours, cells were lysed by using a lysis buffer contained in Dual-Luciferase Reporter Assay System(Cat.# E1910;Promega), and a substrate and ATP were mixed with each other, and then luminescence amount was measured by using Luminometer.

**[0094]** As a result, it was confirmed that promoter activation of NICD exhibited by Notch-1 activation of LS174T cells was decreased in cells treated with the dual-target antibody PMC-201, similar to DAPT treatment groups, as compared to Comparative Group having untreated antibody (FIG. 9).

#### **Example 7: Analysis of increase in Notch Intracellular Domain (NICD) by activation of Notch-1**

**[0095]** 1  $\mu\text{g}/\text{Ml}$  concentration of recombinant hDLL4 was coated with 6-well plate overnight (16 hours), and washed with 1XPBS. Human IgG (hIgG), Tanibirumab, PMC-201 (20  $\mu\text{g}/\text{Ml}$ ) were treated in each well for 1hour, and treated antibody solutions were removed.  $5 \times 10^5$  of HUVEC and IgG, Tanibirumab, PMC-201 (20  $\mu\text{g}/\text{Ml}$ ) were mixed with each other and treated in 6-well plates, respectively. After 24 hours incubation, celles were lysed by using a lysis buffer

(final 1% SDS, 1mM Na<sub>3</sub>VO<sub>4</sub>, 1x protease inhibitor cocktail), and cell solution was collected and transferred to an Eppendorf tube, and heated at 95°C for 10 minutes and cooled in ice. Total protein was quantified by using BCA quantification method, and NICD was measured by the same method as Western blotting of Example 2.

**[0096]** Here, a primary antibody was 1: 1000 dilution of Cleaved Notch1 (Va11744) (D3B8) antibody (Rabbit), β-actin antibody (Rabbit) was 1: 2000 dilution in skim milk containing 5% 0.05% TBST, and a secondary antibody was 1: 1000 dilution of anti-Rabbit IgG (R&D HAF008).

**[0097]** As a result, it was confirmed that an amount of NICD exhibited by hNotch-1 activation in the HUVEC cell was significantly decreased by the dual-target antibody PMC-201 targeting DLL4 as compared to Tanibirumab which is a parent antibody (FIG. 10).

**[0098]** Meanwhile, an analysis method of detecting NICD only by cell culture and co-culture without coating hDLL4 was performed as follows.

**[0099]** First, 5x10<sup>5</sup> cell/well of HUVEC was incubated in 6-well plate for 24 hours. Then, 2.5x10<sup>5</sup> cell/well of 293-hDLL4 (human DLL4 over-expression 293 cell line) and hIgG, PMC-201 (10 μg/ml) DAPT (5 uM) were treated for 1 hour, and antibodies (hIgG, PMC-201) and 293-hDLL4 cells treated with DAPT were added to initially incubated HUVEC in 6-well plates, without removing the antibody solution, and co-cultured for 24 hours. As a comparative group, 293-T cell line was treated and co-cultured with HUVEC.

**[0100]** After co-culture for 24 hours, the cells were lysed by using a lysis buffer (final 1% SDS, 1mM Na<sub>3</sub>VO<sub>4</sub>, 1x protease inhibitor cocktail), and cell solution was collected and transferred to an Eppendorf tube, and heated at 95°C for 10 minutes and cooled in ice. Total protein was quantified by using BCA quantification method, and NICD was measured by the same method as Western blotting of Example 2.

**[0101]** As a result, it was confirmed that an amount of NICD exhibited by Notch-1 activation in the HUVEC cell was decreased to be less than 50% by the dual-target antibody PMC-201 targeting DLL4 as compared to hIgG (FIG. 11).

### **[Industrial Applicability]**

**[0102]** The dual-target antibody according to the present invention may more effectively and simultaneously inhibit signaling of two paths, VEGF/VEGFR-2 and DLL4/Notch1, thereby treating various angiogenesis-related diseases such as tumor, and the like, and particularly, overcoming resistance caused by using a neovascular therapeutic agent alone, and fundamentally preventing recurrence of cancer by directly targeting cancer stem cells.

**[0103]** Therefore, the dual-target antibody according to the present invention and the

pharmaceutical composition including the same may be effectively used for treatment of angiogenesis-related diseases, particularly, cancer.

**[0104]** The present invention has been described in detail based on particular features thereof, and it is obvious to those skilled in the art that these specific technologies are merely preferable embodiments and thus the scope of the present invention is not limited to the embodiments. Therefore, the substantial scope of the present invention is defined by the accompanying claims and equivalent thereof.

<110> PharmAbcine Inc.

<120> Bispecific Antibody Targeting VEGFR-2 and DLL4, and Pharmaceutical Composition Comprising Thereof

<130> PP-B1277

<150> KR 2012-0132431

<151> 2012-11-21

<160> 12

<170> KopatentIn 2.0

<210> 1

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-VEGFR-2 variable heavy chain

<400> 1

```

Ala Gln Pro Ala Met Ala Gln Met Gln Leu Val Gln Ser Gly Ala Glu
 1           5           10           15
Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly
 20           25           30
Tyr Thr Phe Ser Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly
 35           40           45
Gln Arg Leu Glu Trp Met Gly Glu Ile Asn Pro Gly Asn Gly His Thr
 50           55           60
Asn Tyr Asn Glu Lys Phe Lys Ser Arg Val Thr Ile Thr Val Asp Lys
 65           70           75           80
Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
 85           90           95
Thr Ala Val Tyr Tyr Cys Ala Lys Ile Trp Gly Pro Ser Leu Thr Ser
 100          105          110
Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 115          120

```

<210> 2

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; anti-VEGFR-2 variable heavy chain

&lt;400&gt; 2

Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr  
 20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met  
 35 40 45

Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Asn Glu Lys Phe  
 50 55 60

Lys Ser Arg Val Thr Ile Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Lys Ile Trp Gly Pro Ser Leu Thr Ser Pro Phe Asp Tyr Trp Gly  
 100 105 110

Gln Gly Thr Leu  
 115

&lt;210&gt; 3

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; anti-VEGFR-2 variable heavy chain

&lt;400&gt; 3

Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr  
 20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met  
 35 40 45

Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Asn Glu Lys Phe  
 50 55 60

Lys Ser Arg Val Thr Ile Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Lys Ile Trp Gly Pro Ser Leu Thr Ser Pro Phe Asp Tyr Trp Gly  
 100 105 110

Gln Gly Thr Leu

Gln Gly Thr Leu  
115

<210> 4

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-VEGFR-2 variable light chain

<400> 4

```

Ser Gly Val Gly Ser Asn Phe Met Leu Thr Gln Pro Pro Ser Val Ser
 1           5           10           15
Val Ser Pro Gly Lys Thr Ala Arg Ile Thr Cys Arg Gly Asp Asn Leu
          20           25           30
Gly Asp Val Asn Val His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro
          35           40           45
Val Leu Val Met Tyr Tyr Asp Ala Asp Arg Pro Ser Gly Ile Pro Glu
          50           55           60
Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser
          65           70           75           80
Gly Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp
          85           90           95
Arg Thr Ser Glu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
          100          105          110

```

Gly

<210> 5

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-VEGFR-2 variable light chain

<400> 5

```

Asn Phe Met Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Lys
 1           5           10           15
Thr Ala Arg Ile Thr Cys Arg Gly Asp Asn Leu Gly Asp Val Asn Val
          20           25           30
His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Val Leu Val Met Tyr
          35           40           45
Tyr Asp Ala Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
          50           55           60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Val Glu Ala Gly
          65           70           75           80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Arg Thr Ser Glu Tyr
          85           90           95
Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly
          100          105

```

&lt;210&gt; 6

&lt;211&gt; 109

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; anti-VEGFR-2 variable light chain

&lt;400&gt; 6

```

Asn Phe Met Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Lys
 1           5           10           15
Thr Ala Arg Ile Thr Cys Arg Gly Asp Asn Leu Gly Asp Val Asn Val
 20           25           30
His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Val Leu Val Met Tyr
 35           40           45
Tyr Asp Ala Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
 50           55           60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Val Glu Ala Gly
 65           70           75           80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Arg Thr Ser Glu Tyr
 85           90           95
Val Phe Gly Thr Gly Thr Lys Val Glu Ile Lys Arg Thr
 100           105

```

&lt;210&gt; 7

&lt;211&gt; 77

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Notch1 minimal decoy

&lt;400&gt; 7

```

Asp Val Asp Glu Cys Ser Leu Gly Ala Asn Pro Cys Glu His Ala Gly
 1           5           10           15
Lys Cys Ile Asn Thr Leu Gly Ser Phe Glu Cys Gln Cys Leu Gln Gly
 20           25           30
Tyr Thr Gly Pro Arg Cys Glu Ile Asp Val Asn Glu Cys Val Ser Asn
 35           40           45
Pro Cys Gln Asn Asp Ala Thr Cys Leu Asp Gln Ile Gly Glu Phe Gln
 50           55           60
Cys Ile Cys Met Pro Gly Tyr Glu Gly Val His Cys Glu
 65           70           75

```

&lt;210&gt; 8

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> amino acid linker

<400> 8

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser  
 1 5 10

<210> 9

<211> 198

<212> PRT

<213> Artificial Sequence

<220>

<223> bispecific antibody (light chain-Notch1 minimal decoy)

<400> 9

Asp Val Asp Glu Cys Ser Leu Gly Ala Asn Pro Cys Glu His Ala Gly  
 1 5 10 15  
 Lys Cys Ile Asn Thr Leu Gly Ser Phe Glu Cys Gln Cys Leu Gln Gly  
 20 25 30  
 Tyr Thr Gly Pro Arg Cys Glu Ile Asp Val Asn Glu Cys Val Ser Asn  
 35 40 45  
 Pro Cys Gln Asn Asp Ala Thr Cys Leu Asp Gln Ile Gly Glu Phe Gln  
 50 55 60  
 Cys Ile Cys Met Pro Gly Tyr Glu Gly Val His Cys Glu Ser Gly Gly  
 65 70 75 80  
 Gly Gly Ser Gly Gly Gly Ser Gly Ser Asn Phe Met Leu Thr Gln  
 85 90 95  
 Pro Pro Ser Val Ser Val Ser Pro Gly Lys Thr Ala Arg Ile Thr Cys  
 100 105 110  
 Arg Gly Asp Asn Leu Gly Asp Val Asn Val His Trp Tyr Gln Gln Arg  
 115 120 125  
 Pro Gly Gln Ala Pro Val Leu Val Met Tyr Tyr Asp Ala Asp Arg Pro  
 130 135 140  
 Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala  
 145 150 155 160  
 Thr Leu Thr Ile Ser Gly Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr  
 165 170 175  
 Cys Gln Val Trp Asp Arg Thr Ser Glu Tyr Val Phe Gly Thr Gly Thr  
 180 185 190  
 Lys Val Thr Val Leu Gly  
 195

<210> 10

<211> 199

<212> PRT

<213> Artificial Sequence

<220>

<223> bispecific antibody (light chain-Notch1 minimal decoy)

&lt;400&gt; 10

Asp Val Asp Glu Cys Ser Leu Gly Ala Asn Pro Cys Glu His Ala Gly  
 1 5 10 15  
 Lys Cys Ile Asn Thr Leu Gly Ser Phe Glu Cys Gln Cys Leu Gln Gly  
 20 25 30  
 Tyr Thr Gly Pro Arg Cys Glu Ile Asp Val Asn Glu Cys Val Ser Asn  
 35 40 45  
 Pro Cys Gln Asn Asp Ala Thr Cys Leu Asp Gln Ile Gly Glu Phe Gln  
 50 55 60  
 Cys Ile Cys Met Pro Gly Tyr Glu Gly Val His Cys Glu Ser Gly Gly  
 65 70 75 80  
 Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser Asn Phe Met Leu Thr Gln  
 85 90 95  
 Pro Pro Ser Val Ser Val Ser Pro Gly Lys Thr Ala Arg Ile Thr Cys  
 100 105 110  
 Arg Gly Asp Asn Leu Gly Asp Val Asn Val His Trp Tyr Gln Gln Arg  
 115 120 125  
 Pro Gly Gln Ala Pro Val Leu Val Met Tyr Tyr Asp Ala Asp Arg Pro  
 130 135 140  
 Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala  
 145 150 155 160  
 Thr Leu Thr Ile Ser Gly Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr  
 165 170 175  
 Cys Gln Val Trp Asp Arg Thr Ser Glu Tyr Val Phe Gly Thr Gly Thr  
 180 185 190  
 Lys Val Glu Ile Lys Arg Thr  
 195

&lt;210&gt; 11

&lt;211&gt; 2058

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; human DLL4 DNA sequence

&lt;400&gt; 11

atggcgcgtg ccagcagatc tgcctctggc tgggctctgc tgetgctggt ggctctgtgg 60  
 cagcagagag ccgccggaag cggcgtgttc cagctgcagc tccaggagtt catcaacgag 120  
 cggggcgtgc tggccagcgg cagaccttgt gaaccggct gccggacctt cttcagagtg 180  
 tgcctgaagc acttccaggc cgtggtgtcc cccggacct gcaccttgg caccgtgtcc 240  
 acaccctgtc tgggcaccaa cagcttcgcc gtgcgggacg atagcagcgg cggaggcaga 300  
 aacccctgac agctgccctt caacttcacc tggcccggca ccttcagcct gatcatcgag 360  
 gcctggcacg cccctggcga cgacctgagg cctgaagccc tgcctcccga cgccctgatc 420  
 agcaagatcg ccatccaggg cagcctggcc gtgggcccaga actggctgct ggacgagcag 480  
 accagcacc tgaaccggct gcggtacagc tacagagtga tctgcagcga caactactac 540  
 gccgacaact ccagcccgct atgcaagaag cggaaagacc acttcggcca ctacatctac 600

```

cagccccgacg gcaacctgag ctgctgcct ggatggaccg gcgagtactg ccagcagccc      660
atctgcctga gcggtgccca cgagcagaac ggctactgca gcaagcccgc cgagtgcctg      720
tgcagacctg gctggcaggg cagactgtgc aacgagtgca tccccacaa cggctgccgg      780
cacggcacct gtagcacccc ctggcagtgc acctgtgacg agggctgggg cggactgttc      840
tgtgatcagg acctgaacta ctgcacccac cacagcccct gcaagaacgg cgccacatgc      900
agcaacagcg gccagcggag ctacacctgt acctgcagac ccggctacac cggcgtggac      960
tgcgagctgg aactgagcga gtgcgacagc aaccctgcc ggaatggcgg cagctgcaag     1020
gaccaggaag atggtacca ctgctgtgc cccctggct actacggcct gcaactgcgag     1080
cacagcacc tgcctgcgc cgactcccc tgctttaacg gcggtcctg cagagagcgg     1140
aaccagggcg ccaactacgc ctgcgagtgc ccccccaatt tcaccggcag caactgcgag     1200
aagaaagtgg accggtgcac ctccaacccc tgcgccaatg gcggacagtg cctgaacaga     1260
ggccccagcc ggatgtgcag atgcaggcct ggcttcaccg gcacctattg cgagctgcac     1320
gtgtccgact gcgcccgaa tccttgtgcc cacggcggca cctgtcacga cctggaaaac     1380
ggcctgatgt gcacctgtcc tgccggcttc agcggcgga gatgcgaagt gcggaccagc     1440
atcgatgcct gcgcctccag cccctgcttc aaccgggcca cctgttacac cgacctgagc     1500
accgacacct tcgtgtgcaa ctgcccctac ggcttcgtgg gcagcagatg cgagttcccc     1560
gtgggcctgc cccccagctt tccttgggtg gccgtgtctc tggcgtggg cctggctgtg     1620
ctgctggtcc tgctgggaat ggtggccgtg gctgtgcggc agctgagact gagaaggccc     1680
gacgacggca gccgcgaggc catgaacaac ctgagcgact tccagaagga caacctgatc     1740
cctgccgccc agctgaagaa caccaaccag aaaaaagagc tggaaagtcga ctgcggcctg     1800
gacaagagca actgcggcaa gcagcagaac cacaccctgg actacaacct ggcccctggc     1860
cctctgggca gaggcacat gcctggcaag tccccacaa gcgacaagag cctgggagag     1920
aaggcccccc tgagactgca cagcgagaag cccgagtgcc ggatcagcgc catctgcagc     1980
cccagagaca gcatgtacca gagcgtgtgc ctgatctccg aggaacggaa cgagtgcgtg     2040
atcgccaccg aagtgtga                                     2058

```

<210> 12

<211> 686

<212> PRT

<213> Artificial Sequence

<220>

<223> human DLL4 amino acid sequence

<400> 12

```

Met Ala Ala Ala Ser Arg Ser Ala Ser Gly Trp Ala Leu Leu Leu Leu
  1           5           10           15
Val Ala Leu Trp Gln Gln Arg Ala Ala Gly Ser Gly Val Phe Gln Leu
          20           25           30
Gln Leu Gln Glu Phe Ile Asn Glu Arg Gly Val Leu Ala Ser Gly Arg
          35           40           45

```

Pro Cys Glu Pro Gly Cys Arg Thr Phe Phe Arg Val Cys Leu Lys His  
 50 55 60  
 Phe Gln Ala Val Val Ser Pro Gly Pro Cys Thr Phe Gly Thr Val Ser  
 65 70 75 80  
 Thr Pro Val Leu Gly Thr Asn Ser Phe Ala Val Arg Asp Asp Ser Ser  
 85 90 95  
 Gly Gly Gly Arg Asn Pro Leu Gln Leu Pro Phe Asn Phe Thr Trp Pro  
 100 105 110  
 Gly Thr Phe Ser Leu Ile Ile Glu Ala Trp His Ala Pro Gly Asp Asp  
 115 120 125  
 Leu Arg Pro Glu Ala Leu Pro Pro Asp Ala Leu Ile Ser Lys Ile Ala  
 130 135 140  
 Ile Gln Gly Ser Leu Ala Val Gly Gln Asn Trp Leu Leu Asp Glu Gln  
 145 150 155 160  
 Thr Ser Thr Leu Thr Arg Leu Arg Tyr Ser Tyr Arg Val Ile Cys Ser  
 165 170 175  
 Asp Asn Tyr Tyr Gly Asp Asn Cys Ser Arg Leu Cys Lys Lys Arg Asn  
 180 185 190  
 Asp His Phe Gly His Tyr Val Cys Gln Pro Asp Gly Asn Leu Ser Cys  
 195 200 205  
 Leu Pro Gly Trp Thr Gly Glu Tyr Cys Gln Gln Pro Ile Cys Leu Ser  
 210 215 220  
 Gly Cys His Glu Gln Asn Gly Tyr Cys Ser Lys Pro Ala Glu Cys Leu  
 225 230 235 240  
 Cys Arg Pro Gly Trp Gln Gly Arg Leu Cys Asn Glu Cys Ile Pro His  
 245 250 255  
 Asn Gly Cys Arg His Gly Thr Cys Ser Thr Pro Trp Gln Cys Thr Cys  
 260 265 270  
 Asp Glu Gly Trp Gly Gly Leu Phe Cys Asp Gln Asp Leu Asn Tyr Cys  
 275 280 285  
 Thr His His Ser Pro Cys Lys Asn Gly Ala Thr Cys Ser Asn Ser Gly  
 290 295 300  
 Gln Arg Ser Tyr Thr Cys Thr Cys Arg Pro Gly Tyr Thr Gly Val Asp  
 305 310 315 320  
 Cys Glu Leu Glu Leu Ser Glu Cys Asp Ser Asn Pro Cys Arg Asn Gly  
 325 330 335  
 Gly Ser Cys Lys Asp Gln Glu Asp Gly Tyr His Cys Leu Cys Pro Pro  
 340 345 350  
 Gly Tyr Tyr Gly Leu His Cys Glu His Ser Thr Leu Ser Cys Ala Asp  
 355 360 365  
 Ser Pro Cys Phe Asn Gly Gly Ser Cys Arg Glu Arg Asn Gln Gly Ala  
 370 375 380  
 Asn Tyr Ala Cys Glu Cys Pro Pro Asn Phe Thr Gly Ser Asn Cys Glu  
 385 390 395 400  
 Lys Lys Val Asp Arg Cys Thr Ser Asn Pro Cys Ala Asn Gly Gly Gln  
 405 410 415  
 Cys Leu Asn Arg Gly Pro Ser Arg Met Cys Arg Cys Arg Pro Gly Phe  
 420 425 430  
 Thr Gly Thr Tyr Cys Glu Leu His Val Ser Asn Cys Ala Arg Asp Pro

```

435
Cys Ala His Gly Gly Thr Cys His Asp Leu Glu Asn Gly Leu Met Cys
450
Thr Cys Pro Ala Gly Phe Ser Gly Arg Arg Cys Glu Val Arg Thr Ser
465
Ile Asp Ala Cys Ala Ser Ser Pro Cys Phe Asn Arg Ala Thr Cys Tyr
485
Thr Asp Leu Ser Thr Asp Thr Phe Val Cys Asn Cys Pro Tyr Gly Phe
500
Val Gly Ser Arg Cys Glu Phe Pro Val Gly Leu Pro Pro Ser Phe Pro
515
Trp Val Ala Val Ser Leu Gly Val Gly Leu Ala Val Leu Leu Val Leu
530
Leu Gly Met Val Ala Val Ala Val Arg Gln Leu Arg Leu Arg Arg Pro
545
Asp Asp Gly Ser Arg Glu Ala Met Asn Asn Leu Ser Asp Phe Gln Lys
565
Asp Asn Leu Ile Pro Ala Ala Gln Leu Lys Asn Thr Asn Gln Lys Lys
580
Glu Leu Glu Val Asp Cys Gly Leu Asp Lys Ser Asn Cys Gly Lys Gln
595
Gln Asn His Thr Leu Asp Tyr Asn Leu Ala Pro Gly Pro Leu Gly Arg
610
Gly Thr Met Pro Gly Lys Phe Pro His Ser Asp Lys Ser Leu Gly Glu
625
630
635
640
Lys Ala Pro Leu Arg Leu His Ser Glu Lys Pro Glu Cys Arg Ile Ser
645
650
655
Ala Ile Cys Ser Pro Arg Asp Ser Met Tyr Gln Ser Val Cys Leu Ile
660
665
670
Ser Glu Glu Arg Asn Glu Cys Val Ile Ala Thr Glu Val ***
675
680
685

```

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description

- [EP1916001A2 \[0008\]](#)

- [GB0204619W](#) [0008]
- [WO2008153237A](#) [0008] [0010]
- [US20100260668A1](#) [0020]
- [KR07003077W](#) [0072]
- [KR20120132431](#) [0104]

#### Non-patent literature cited in the description

- **RISAU** Nature, 1997, vol. 386, 671- [0002]
- **CARMELIET JAIN** Nature, 2000, vol. 407, 249- [0002]
- **FERRARAKERBEL** Nature, 2005, vol. 438, 967- [0003]
- **LEUNG et al.** Science, 1989, vol. 246, 1306- [0005]
- **TISHER et al.** J. Biol. Chem., 1991, vol. 266, 11947- [0005]
- **ELLISHICKLIN** Nature Rev. Cancer, 2008, vol. 8, 579- [0005]
- **YOUSOUFIAN et al.** Clin. Cancer Res., 2007, vol. 13, 5544s- [0005]
- **FERRARA et al.** Biochem. Biophys. Res. Comm., 2005, vol. 333, 328- [0006]
- **ETER et al.** Biodrgus, 2006, vol. 20, 167- [0006]
- **HOLASH et al.** PNAS, 2002, vol. 99, 11393- [0007]
- **DUFRAINE et al.** Oncogene, 2008, vol. 27, 5132-5137 [0012]
- **BRAY SJ** Nat Rev Mol Cell Biol., 2006, vol. 7, 9678- [0013]
- **YAN M** Vasc Cell, 2011, [0015]
- **DUARTE et al.** Genes Dev, 2004, [0015]
- **GALE et al.** PNAS, 2004, [0015]
- **KREBS et al.** Genes Dev, 2004, [0015]
- **THURSTON et al.** Nat Rev Cancer, 2007, vol. 7, 5327- [0016]
- **RIDGWAY et al.** Nature, 2006, vol. 444, 71221083- [0017] [0018]
- **NOGUERA-TROISE et al.** Nature, 2006, vol. 444, 71221032- [0018]
- **HOEY et al.** Cell Stem Cell, 2009, [0019]
- **WANG et al.** Biochim Biophys Acta., 2010, vol. 1806, 2258- [0019]
- **SAMBROOK et al.** Molecular Cloning: A laboratory Manual Cold Spring Harbor Laboratory Press 19890000 [0058]
- **DEUSCHER, M.** Guide to Protein Purification Methods Enzymology Academic Press. Inc. 19900000 vol. 182, [0058]
- **ANDREA GELING et al.** EMBO Rep., 2002, vol. 3, 7688- [0092]
- **IE-MING SHIHTIAN-LI WANG** Cancer Research, 2007, vol. 67, 1879- [0092]

**Patentkrav**

- 5           **1.** Dual-target-antistof målrettet mod VEGFR-2 og DLL4, omfattende en DLL4-antagonist, der er bundet til en terminus af et antistof, der binder til VEGFR-2, hvor antistoffet, der binder til VEGFR-2, omfatter en tungkæde-variabel region omfattende en sekvens udvalgt fra gruppen bestående af SEQ ID NOs:1 til 3 og en letkæde-variabel region omfattende en sekvens udvalgt fra gruppen bestående af SEQ ID NOs:4 til 6, hvor DLL4-antagonisten er det 11. og 12. calcium-bindende EGF-lignende domæne af humant Notch1, og
- 10           hvor DLL4-antagonisten er bundet til en N-terminal af en letkæde-variabel region af antistoffet, der binder til VEGFR-2.
- 15           **2.** Dual-target-antistof ifølge krav 1, hvor DLL4-antagonisten er bundet til antistoffet, der binder til VEGFR-2, via en aminosyre-linker.
- 20           **3.** Dual-target-antistof ifølge krav 1, hvor antistoffet, der binder til VEGFR-2, omfatter en tungkæde-variabel region omfattende en sekvens med SEQ ID NO: 1 og en letkæde-variabel region omfattende en sekvens med SEQ ID NO: 4; en tungkæde-variabel region omfattende en sekvens med SEQ ID NO: 2 og en letkæde-variabel region omfattende en sekvens med SEQ ID NO: 5; eller en tungkæde-variabel region omfattende en sekvens med SEQ ID NO: 3 og en letkæde-variabel region omfattende en sekvens med SEQ ID NO: 6.
- 25           **4.** Dual-target-antistof ifølge krav 1, hvor DLL4-antagonisten 11. og 12. calcium-bindende EGF-lignende domæne af humant Notch1 omfatter en sekvens med SEQ ID NO: 7.
- 30           **5.** DNA, der koder for et dual-target-antistof ifølge et hvilket som helst af kravene 1 til 4.
- 6.** Rekombinant ekspressionsvektor omfattende DNA ifølge krav 5.

7. Værtscelle, der er transformeret med den rekombinante vektor ifølge krav 6.
- 5 8. Fremgangsmåde til fremstilling af et dual-target-antistof ifølge et hvilket som helst af kravene 1 til 4, omfattende at dyrke værtscellen ifølge krav 7 og at isolere dual-target-antistoffet fra kulturen.
- 10 9. Farmaceutisk sammensætning til anvendelse til behandling af angiogenese-relaterede sygdomme, omfattende dual-target-antistoffet ifølge et hvilket som helst af kravene 1 til 4, hvor de angiogenese-relaterede sygdomme er en eller flere udvalgt fra gruppen bestående af tumorvækst, tumormetastase, aldersrelateret makuladegeneration (ARMD), diabetisk retinopati, psoriasis, reumatoid arthritis og kronisk inflammation.
- 15 10. Sammensætning til anvendelse til behandling af angiogenese-relaterede sygdomme ifølge krav 9, hvor tumoren er en eller flere udvalgt fra gruppen bestående af coloncancer, kolorektal cancer, gastrisk cancer, brystcancer, lungecancer, ovariecancer, levercancer, bronkialcancer, nasopharyngeal cancer, strubecancer, pancreascancer, blærecancer, pancreascancer, cervixcancer, 20 hjernecancer, prostatacancer, knoglecancer, hudcancer, thyreoideacancer, parathyroideacancer, nyrecancer, øsofaguscancer, galdevejscancer, testikelcancer, rektalcancer, hoved- og halscancer, cervixcancer, uretercancer, osteosarkom, neurocytom, melanom, fibrosarkom, rhabdomyosarkom, astrocytom, neuroblastom og neurogliom.

# DRAWINGS

FIG. 1

DVDEC SLGAN PCEHA GKCIN  
 TLGSF ECQCL QGYTG PRCEI  
 DVNEC VSNPC QNDAT CLDQI  
 GEFQC ICMPG YEGVH CE

FIG. 2




FIG. 3




FIG. 4




FIG. 5

## Binding Affinity of PMC-201 to human Ag-X (Biacore)

	Ka(1/Ms)	Kd(1/s)	KD (M)
PMC-201	$2.74 \times 10^4$	$3.88 \times 10^{-4}$	$1.42 \times 10^{-8}$
Human Notch1-Fc	$6.09 \times 10^4$	$1.22 \times 10^{-3}$	$1.99 \times 10^{-8}$

FIG. 6

Cell : DLL4-overexpressing 293 (pool)






FIG. 7



VEGF (20ng/ml)	—	+	+	+	+	+	+
Tanibirumab (nM)	—	—	6.7	66.7	—	—	—
PMC-201 (nM)	—	—	—	—	6.7	66.7	—
Human Notch1-Fc (nM)	—	—	—	—	—	—	6.7

FIG. 8



	—	—	—	—
hNotch-Fc-FITC (1 µg/ml)	-	+	+	+
Geo Mean	4.18	31.57	26.50	9.73
Competing Abs (16 µg/ml)	-	-	Tanibiru mab	PMC- 201

FIG. 9




FIG. 10




FIG. 11

